Q-omics provides the consensus-scored MPV17L profile across patient tissues and cancer cell-line models. MPV17L expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MPV17L is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, MPV17L RNA expression shows 17,296 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where MPV17L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MPV17L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MPV17L survival associations across molecular data types. MPV17L RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MPV17L RNA expression–survival associations across cancer types. High MPV17L expression shows unfavorable associations in UVM, LAML and LGG, but favorable associations in KIRC, KIRP and KICH. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MPV17L RNA expression.
This table summarizes MPV17L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for MPV17L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MPV17L shows lower tumor expression in HNSC, KICH, BLCA, UCEC and THCA and higher tumor expression in LIHC. The HNSC box plot shows higher MPV17L RNA expression in normal versus tumor tissue (log2 FC = −1.641, t-test p < 0.001).
This table shows molecular features associated with MPV17L in patient tissues and cancer cell lines. In patient samples, MPV17L shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MPV17L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
